

APPLICATION NO.  
10/766,752

FILING DATE  
January 27, 2004

CONFIRMATION NO. 2963	GROUP 1646
--------------------------	---------------

**June 1, 2004**

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

**AT2**

**Press Release: Chrysalis BioTechnology to begin clinical trials, (September 24, 1998).**

**AU2**


**Press Release: Chrysalis Announces Completion of Pilot Chrysalin® Clinical Trial for Diabetic Ulcers, (August 21, 2001).**

EXAMINER

DATE CONSIDERED


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>January 27, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. <b>3033.1008-008</b>		CONTINUATION APPLICATION OF NO. <b>PCT/US02/01151</b>	
	FIRST NAMED INVENTOR <b>Darrell H. Carney</b>		FILING DATE	
	EXAMINER		CONFIRMATION NO.	GROUP

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
RM	AA	5,352,664	10-04-1994	Carney <i>et al.</i>
RM	AB	5,500,412	03-19-1996	Carney <i>et al.</i>
	AC			
	AD			
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER 	DATE CONSIDERED <b>04-04-05</b>
---	------------------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  January 27, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3033.1008-008		CONTINUATION APPLICATION OF NO. PCT/US02/01151	
	FIRST NAMED INVENTOR Darrell H. Carney		FILING DATE	
	EXAMINER		CONFIRMATION NO.	GROUP

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
RR	AL	WO 01/49309 A2	07-12-2001	Pfizer Limited	
RR	AM	WO 88/03151	05-05-1988	Board of Regents, The University of Texas System	
	AN				
	AO				
	AP				
	AQ				
	AL2				
	AM2				
	AN2				
	AO2				
	AP2				
	AQ2				
	AL3				
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AQ4				

EXAMINER 	DATE CONSIDERED 04-04-05
---	-----------------------------

PTO-1449, REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  January 27, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3033.1008-008		CONTINUATION APPLICATION OF NO. PCT/US02/01151	
	FIRST NAMED INVENTOR Darrell H. Carney		FILING DATE	
	EXAMINER	CONFIRMATION NO.	GROUP	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR	Stiernberg, J., <i>et al.</i> , "Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508," <i>Wound Repair and Regeneration</i> , 8(3):204-215 (2000).	
AS	Norfleet, A.M., <i>et al.</i> , "Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells," <i>General Pharmacology</i> , 35:249-254 (2002).	
AT	Norfleet, A.M., <i>et al.</i> , "Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia," <i>Wound Repair and Regeneration</i> , 8(6):517-529 (2000).	
AU	Pernia, S.D., <i>et al.</i> , "A Synthetic Peptide Representing the Thrombin Receptor-Binding Domain Enhances Wound Closure <i>In Vivo</i> ," <i>SAAS Bulletin: Biochem. &amp; Biotech.</i> , 3:8-12 (1990).	
AV	Carney, Darrell H., "Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors," In <i>Thrombin Structure and Function</i> , Berliner, L.J. (ed.) (New York: Plenum Press), pp. 351-396 (1992).	
AW	Stiernberg, J., <i>et al.</i> , "The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair," <i>Thrombosis and Haemostasis</i> , 70(1):158-162 (1993).	
AX	Carney, D.H., <i>et al.</i> , "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides," <i>J. Clin. Invest.</i> , 89:1469-1477 (1992).	
AY	Carney, D.H., <i>et al.</i> , "Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin," <i>Seminars in Thrombosis and Hemostasis</i> , 18(1):91-102 (1992).	
AZ	Glenn, K.C., <i>et al.</i> , "Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis," <i>Peptide Research</i> , 1(2):65-73 (1988).	
AR2	Sower, L.E., <i>et al.</i> , "Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway," <i>Experimental Cell Research</i> , 247:422-431 (1999).	
AS2	Steed, D.L., <i>et al.</i> , "Promotion and Acceleration of Diabetic Ulcer Healing by Arginine-Glycine-Aspartic Acid (RGD) Peptide Matrix," <i>Diabetes Care</i> , 18(1):39-46 (1995).	

EXAMINER 	DATE CONSIDERED 04-04-05
---	-----------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3033.1008-008APPLICATION NO.  
10/766,752INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION

February 28, 2005

(Use several sheets if necessary)

FIRST NAMED INVENTOR  
Darrell H. CarneyFILING DATE  
January 27, 2004EXAMINER  
Mondesi, Robert B.CONFIRMATION NO.  
2963GROUP  
1653

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
RR	AN	WO 96/40033	12/19/1996	Clarion Pharmaceuticals, Inc.		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	AV2	Hollenberg, Morley D., <i>et al.</i> , "Synergistic Actions of a Thrombin-Derived Synthetic Peptide and a Thrombin Receptor-Activating Peptide in Stimulating Fibroblast Mitogenesis," <i>J. Cell Physiol.</i> 169:491-496 (1996).

EXAMINER

Robert B. Mondesi

DATE CONSIDERED

04-04-05